Randomized Phase 2 Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer

Simple item page
dc.contributor.authorSequist, L.
dc.contributor.authorGray, J.
dc.contributor.authorHarb, W.
dc.contributor.authorDoebele, R.
dc.contributor.authorModiano, M.
dc.contributor.authorJackman, D.
dc.contributor.authorBaggstrom, M.
dc.contributor.authorAtmaca, A.
dc.contributor.authorFelip, E.
dc.contributor.authorProvencio, M.
dc.contributor.authorCobo Dols, M.
dc.contributor.authorAdiwijaya, B.
dc.contributor.authorKuesters, G.
dc.contributor.authorKamoun, W.
dc.contributor.authorAndreas, K.
dc.contributor.authorPipas, J.
dc.contributor.authorSantillana, S.
dc.contributor.authorCho, B. C.
dc.contributor.authorPark, K.
dc.contributor.authorShepherd, F.
dc.contributor.authoraffiliation[Sequist, L.] Massachusetts Gen Hosp, Boston, MA 02114 USA
dc.contributor.authoraffiliation[Gray, J.] H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol, Tampa, FL USA
dc.contributor.authoraffiliation[Harb, W.] Horizon Oncol Ctr, Lafayette, IN USA
dc.contributor.authoraffiliation[Doebele, R.] Univ Colorado, Div Med Oncol, Aurora, CO USA
dc.contributor.authoraffiliation[Modiano, M.] 6 Arizona Clin Res Ctr, Tucson, AZ USA
dc.contributor.authoraffiliation[Jackman, D.] Dana Farber Canc Inst, Boston, MA 02115 USA
dc.contributor.authoraffiliation[Baggstrom, M.] Washington Univ, Sch Med, St Louis, MO USA
dc.contributor.authoraffiliation[Atmaca, A.] Uct Univ Canc Ctr, Inst Clin Res Ikf Krankenhaus Nordwest, Frankfurt, Germany
dc.contributor.authoraffiliation[Felip, E.] Vall dHebron Univ Hosp, Barcelona, Spain
dc.contributor.authoraffiliation[Provencio, M.] Hosp Puerta Hierro Majadahonda, Madrid, Spain
dc.contributor.authoraffiliation[Cobo Dols, M.] Hosp Reg Univ Carlos Haya, Hosp Gen, Malaga, Spain
dc.contributor.authoraffiliation[Adiwijaya, B.] Merrimack Pharmaceut Inc, Cambridge, MA USA
dc.contributor.authoraffiliation[Kuesters, G.] Merrimack Pharmaceut Inc, Cambridge, MA USA
dc.contributor.authoraffiliation[Kamoun, W.] Merrimack Pharmaceut Inc, Cambridge, MA USA
dc.contributor.authoraffiliation[Andreas, K.] Merrimack Pharmaceut Inc, Cambridge, MA USA
dc.contributor.authoraffiliation[Pipas, J.] Merrimack Pharmaceut Inc, Cambridge, MA USA
dc.contributor.authoraffiliation[Santillana, S.] Merrimack Pharmaceut Inc, Cambridge, MA USA
dc.contributor.authoraffiliation[Cho, B. C.] Yonsei Canc Ctr, Med Oncol, Seoul, South Korea
dc.contributor.authoraffiliation[Park, K.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
dc.contributor.authoraffiliation[Shepherd, F.] Princess Margaret Canc Ctr, Toronto, ON, Canada
dc.date.accessioned2025-01-07T12:15:00Z
dc.date.available2025-01-07T12:15:00Z
dc.date.issued2018-10-01
dc.identifier.doi10.1016/j.jtho.2018.08.893
dc.identifier.essn1556-1380
dc.identifier.issn1556-0864
dc.identifier.unpaywallURLhttp://www.jto.org/article/S1556086418318513/pdf
dc.identifier.urihttps://hdl.handle.net/10668/24369
dc.identifier.wosID454014502048
dc.issue.number10
dc.issue.numberS
dc.journal.titleJournal of thoracic oncology
dc.journal.titleabbreviationJ. thorac. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.page.numberS596-S596
dc.publisherElsevier science inc
dc.rights.accessRightsopen access
dc.subjectbiomarker
dc.subjectSeribantumab
dc.subjectHeregulin
dc.titleRandomized Phase 2 Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number13
dc.wostypeMeeting Abstract

Files

Collections

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía